Amplimmune Immunology
Founded Year
2000Stage
Acquired | AcquiredTotal Raised
$20MValuation
$0000About Amplimmune Immunology
Amplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Amplimmune's scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors. These immunological checkpoint and co-stimulatory molecules are the basis for developing a new class of biological treatments which modulate critical mechanisms in the body's immune system with the aim of bettering the lives of patients suffering from aberrant immunological conditions.
Missing: Amplimmune Immunology's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Amplimmune Immunology's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Amplimmune Immunology
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Amplimmune Immunology is included in 2 Expert Collections, including Cancer.
Cancer
1,179 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Amplimmune Immunology Patents
Amplimmune Immunology has filed 12 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/27/2014 | 6/11/2019 | Clusters of differentiation, Immunology, Immune system, Transcription factors, Monoclonal antibodies | Grant |
Application Date | 5/27/2014 |
|---|---|
Grant Date | 6/11/2019 |
Title | |
Related Topics | Clusters of differentiation, Immunology, Immune system, Transcription factors, Monoclonal antibodies |
Status | Grant |
Amplimmune Immunology Frequently Asked Questions (FAQ)
When was Amplimmune Immunology founded?
Amplimmune Immunology was founded in 2000.
Where is Amplimmune Immunology's headquarters?
Amplimmune Immunology's headquarters is located at 45 West Watkins Mill Road, Gaithersburg.
What is Amplimmune Immunology's latest funding round?
Amplimmune Immunology's latest funding round is Acquired.
How much did Amplimmune Immunology raise?
Amplimmune Immunology raised a total of $20M.
Who are the investors of Amplimmune Immunology?
Investors of Amplimmune Immunology include MedImmune, InterWest Partners and Wellcome Trust.
Who are Amplimmune Immunology's competitors?
Competitors of Amplimmune Immunology include ISA Pharmaceuticals, Activate Immunotherapy, Syndax Pharmaceuticals, Theraclone Sciences, FibroGen and 12 more.
Compare Amplimmune Immunology to Competitors
Theraclone Sciences, formerly Spaltudaq, is a biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The companys technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human subjects. Human monoclonal antibodies can be rapidly isolated using the ISTAR discovery platform and scaled for industrial production. Such human antibody drug candidates may be uniquely safe and relevant to combating disease across broad patient populations.
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
BioMs develops biologics for autoimmune diseases with a special emphasis on multiple sclerosis.
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.
Neotropix 1 is a virotherapy company, dedicated to the development and commercialization of virus-based therapies for the treatment of cancer and other diseases. Per Neotropix, virotherapy holds great promise for cancer patients because it may be more efficacious and less toxic than conventional radiation and chemotherapy.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.